The specific embodiment
Technical solution of the present invention is not limited to the following cited specific embodiment, also comprises any combination between each specific embodiment.
The specific embodiment one: the present embodiment health products for reducing fat is made up of 1: 1 tablet A and tablet B by mass percentage; Wherein tablet A is made up of 10.0%~20.0% chitosan, 25.0%~35.0% l-cn, 0.01%~0.06% pyridine acid chrome, 25.0%~35.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage; Tablet B is made up of 4.0%~8.0% mixed vitamin, 30.0%~40.0% mixed mineral matter, 30.0%~40.0% leukotrienes and the auxiliary material of surplus by weight percentage.
The chitosan that adds among the present embodiment tablet A is the polymer substance that has positive charge, and the superabundant fats in the human body is electronegative, thus Weight-lossing hypolipemic medicine by adding the superabundant fats in the chitosan adsorbent, and after metabolism excrete.
Adding l-cn among the present embodiment tablet A mainly is as carrier LCFA to be transported to promote oxidation of fatty acids in the film outside mitochondrial membrane, become the energy that needed by human body is wanted, reduce fat, reduced body weight, also strengthened the ability of cardiac muscle cell's oxidation of fat, the burden of heart, the people's that slows down aging course when promoting fatigue recovery, reduction high-intensity exercise.
The adding pyridine acid chrome can significantly reduce T-CHOL and the triglyceride level in the high fat of blood body serum among the present embodiment tablet A, improves hdl level.Simultaneously, pyridine acid chrome also has inhibitory action to body weight, the increase of body fat.The chromium that pyridine acid chrome contains also can be used as the active component of GTF, participates in regulating the carbohydrate and the fatty metabolism of body, will help to strengthen the sensitiveness of insulin, promotes the utilization of peripheral tissues to glucose.
The CALCIUM PYRUVIC that adds among the present embodiment tablet A can directly enter in the body, by osmosis the aliphatic acid in the body (mainly being long chain type) oxidizing fire is fallen, and makes fat reduce (consuming 48% fat at least), body weight decline.CALCIUM PYRUVIC can be used as the calcium nutritious supplementary pharmaceutical, though calcium content less than 30% is in the present invention participated in organic metabolism directly after it enters cell, can reach the effect of fat-reducing and not exist influences hepatic and renal function, has no side effect.
Adding mixed vitamin and mixed mineral matter can be improved overweight people's glycometabolism, fat metabolism and hormone metabolism disorder among the present embodiment tablet B, and then bring into play the effect of Weight-reducing and lipid-lowering on the basis of correcting whole metabolic disorder.
The gamma-Linolenic acid that adds among the present embodiment tablet B is one of essential fatty acid with extensive physiologically active and obviously pharmacological action of forming each tissue biological's membrane structure of human body, absorption by reducing exogenous lipid and endogenous lipid synthetic, promote the transhipment and the drainage of lipid, regulate the effect that fat metabolism realizes lipopenicillinase and fat-reducing.
The specific embodiment two: the difference of the present embodiment and the specific embodiment one is: tablet A is made up of 12.0%~18.0% chitosan, 28.0%~32.0% l-cn, 0.02%~0.04% pyridine acid chrome, 28.0%~32.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage.Other is identical with the specific embodiment one.
The specific embodiment three: the difference of the present embodiment and the specific embodiment one is: tablet A is made up of 15.0% chitosan, 30.0% l-cn, 0.03% pyridine acid chrome, 30.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage.Other is identical with the specific embodiment one.
The specific embodiment four: the difference of the present embodiment and the specific embodiment one is: the auxiliary material among the tablet A is calcium monohydrogen phosphate, dolomol, sorbierite, aspartame and superfine silica gel powder.Other is identical with the specific embodiment one.
The specific embodiment five: the difference of the present embodiment and the specific embodiment one is: tablet B is made up of 5.0%~7.0% mixed vitamin, 32.0%~38.0% mixed mineral matter, 32.0%~38.0% leukotrienes and the auxiliary material of surplus by weight percentage.Other is identical with the specific embodiment one.
The specific embodiment six: the difference of the present embodiment and the specific embodiment one is: tablet B is made up of 6.0% mixed vitamin, 35.0% mixed mineral matter, 35.0% leukotrienes and the auxiliary material of surplus by weight percentage.Other is identical with the specific embodiment one.
The specific embodiment seven: the difference of the present embodiment and the specific embodiment one is: the content of vitamin A is that the content of 164~263 μ g/g, bata-carotene is 0.3~1.0mg/g, Cobastab in the mixed vitamin among the tablet B
1Content be 0.3~0.6mg/g, Cobastab
2Content be 0.3~0.6mg/g, Cobastab
6Content be that 0.3~0.6mg/g, ascorbic content are 10.0~30.0mg/g, Cobastab
12Content be that the content of 0.5~2.0 μ g/g, vitamin D is that the content of 1.0~3.0 μ g/g, vitamin E is that the content of 2.0~7.0mg/g, biotin is that the content of 5.0~10.0 μ g/g, folic acid is that the content of 60.0~131.0 μ g/g, nicotinic acid is that the content of 3.0~4.9mg/g, pantothenic acid is 1.0~3.0mg/g.Other is identical with the specific embodiment one.
Mixed vitamin can participate in improving overweight people's metabolic disorder in the present embodiment.
The specific embodiment eight: the difference of the present embodiment and the specific embodiment one is: among the tablet B in the mixed mineral matter content of zinc be that the content of 2.0~5.0mg/g, potassium is that the content of 10.0~30.0mg/g, copper is that the content of 0.2~0.49mg/g, manganese is that the content of 0.3~0.9mg/g, iodine is that the content of 30.0~60.0 μ g/g, iron is that the content of 4.0~6.5mg/g, selenium is that the content of 6.0~10.0 μ g/g, magnesium is that the content of 60~98mg/g, molybdenum is 6.0~10.0 μ g/g.Other is identical with the specific embodiment one.
Zinc in the present embodiment in the mixed mineral matter will the phosphorylation process of tyrosine acceptor have been brought into play the sensitiveness that potential effect also can be strengthened insulin in insulin signaling transduction process, promote the utilization of peripheral tissues to glucose; Iron can significantly reduce the body fat content of obese individuals and strengthen its lean body mass; Magnesium is of value to the raising of beta Cell of islet respond and insulin active.
The specific embodiment nine: the difference of the present embodiment and the specific embodiment one is: the auxiliary material among the tablet B is calcium monohydrogen phosphate, superfine silica gel powder, dolomol, aspartame and flavoring pineapple essence.Other is identical with the specific embodiment one.
The specific embodiment ten: the difference of the present embodiment and the specific embodiment one is: linolenic mass concentration is 10% among the tablet B.Other is identical with the specific embodiment one.
The specific embodiment 11: the present embodiment health products for reducing fat is made up of 1: 1 tablet A and tablet B by mass percentage; Wherein tablet A is made up of 15.0% chitosan, 30.0% l-cn, 0.05% pyridine acid chrome, 30.0% CALCIUM PYRUVIC and the auxiliary material of surplus by weight percentage; Tablet B is made up of 6.0% mixed vitamin, 35.0% mixed mineral matter, 35.0% leukotrienes and the auxiliary material of surplus by weight percentage.
With this implement resulting tablet A by every day dose be 2~4g/ days people dosage every day breakfast, lunch and dinner temperature half an hour ante cibum boiling water take; With this implement resulting tablet B by every day dose be that the temperature boiling water is taken continuous 45 days half an hour after every day breakfast, lunch and dinner for 2~4g/ days people's dosage.
Adopt double-blind study that experimenter group is divided into test-meal group (crowd of edible this product in a manner described) and control group (crowd of edible placebo) at random, carry out the fat-reducing effect test.
Table 1 is the basic document of test-meal group and control group.
Table 1
Project |
The test-meal group |
Control group |
The example number |
50 |
50 |
Man/woman |
24/26 |
23/27 |
Age (year) |
43.33±8.42 |
43.36±10.72
※ |
The course of disease (year) |
10.27±3.79 |
10.55±3.98
※ |
Body weight (kilogram) |
77.83±8.27 |
77.35±9.73
※ |
Body mass index (%) |
29.40±3.65 |
29.03±2.73
※ |
Fat percentage (%) |
34.58±4.90 |
34.85±4.65
※ |
Contrast between the ※ group: P>0.05.
The preceding two groups of patient ages of test-meal, the course of disease, body weight, body mass index and the equal no significant difference of fatty percentage (P>0.05) have comparativity as can be seen from Table 1, and the data that record will have reliability and near True Data.
Table 2 is the (X ± SD) show of changes of weight before and after the test-meal.
Table 2
Grouping |
Body weight (kg) before the test-meal |
Body weight after the test-meal (kg) |
Difference |
The test-meal group |
77.83±8.27 |
74.66±8.09
*※ |
-3.17±1.56 |
Control group |
77.35±9.73 |
77.08±9.74 |
-0.28±1.24 |
Compare between test front and back self and group: * own control P<0.05 contrasts P<0.05 between the ※ group.
The test-meal group as can be seen from Table 2 test forebody-afterbody method of double differences is different conspicuousness (P<0.05), the weight average 3.17 ± 1.56Kg that descends; Test back test-meal group body weight and control group comparing difference have conspicuousness (P<0.05), prove absolutely that given the test agent has the effect that reduces body weight.
Table 3 changes (X ± SD) show for test-meal forebody-afterbody fat mass.
Table 3
Grouping |
Fat mass (kg) before the test-meal |
Fat mass after the test-meal (kg) |
Difference |
The test-meal group |
27.36±5.87 |
24.52±4.41
*※ |
-2.83±1.19 |
Control group |
27.03±4.97 |
27.26±5.29 |
0.24±1.36 |
Compare between test front and back self and group: * own control P<0.05 contrasts P<0.05 between the ※ group.
Test-meal group as can be seen from Table 3 test forebody-afterbody fat mass difference has conspicuousness (P<0.05), the body fat amount 2.83 ± 1.19Kg that on average descends; Test back test-meal group body fat amount and control group comparing difference have conspicuousness (P<0.05), illustrate that given the test agent has the effect that reduces the body fat amount.
Table 4 is the (X ± SD) show of fatty percentage change before and after the test-meal.
Table 4
Grouping |
Fatty percentage (%) before the test-meal |
Fatty percentage (%) after the test-meal |
Difference |
The test-meal group |
34.58±3.90 |
31.27±3.79
*※ |
-3.31±1.59 |
Control group |
34.85±4.65 |
34.93±4.27 |
0.09±1.04 |
Compare between test front and back self and group: * own control P<0.05 contrasts P<0.05 between the ※ group.
Fatty percentage difference has conspicuousness (P<0.05) before and after the test of test-meal group as can be seen from Table 4, on average descends 3.31 ± 1.59%; Test back test-meal group body fat percentage and control group comparing difference have conspicuousness (P<0.05), illustrate that given the test agent has the fatty percentile effect of reduction.
Table 5 changes (X ± SD) for the test-meal front and back waist.
Table 5
Grouping |
Waistline (cm) before the test-meal |
Waistline after the test-meal (cm) |
Difference |
The test-meal group |
94.21±8.11 |
90.03±9.48
*※ |
-4.18±3.00 |
Control group |
94.06±8.49 |
94.53±9.33 |
0.46±1.54 |
Compare between test front and back self and group: * own control P<0.05 contrasts P<0.05 between the ※ group.
The test of test-meal group as can be seen from Table 5 front and back waist difference has conspicuousness (P<0.05), waistline decreased average 4.18 ± 3.00cm; Test back test-meal group waistline and control group comparing difference have conspicuousness (P<0.05), illustrate that given the test agent has the effect that reduces waistline.
Table 6 changes (X ± SD) show for hip circumference before and after the test-meal.
Table 6
Grouping |
Test-meal front hip circumference (cm) |
Hip circumference after the test-meal (cm) |
Difference |
The test-meal group |
105.99±8.74 |
103.81±9.13 |
-2.18±3.47 |
Control group |
105.86±5.02 |
105.02±5.09 |
-0.84±2.46 |
After the test of test-meal group as can be seen from Table 6, hip circumference has reduced by 2.18 ± 3.47cm.
Table 7 changes (X ± SD) show for right angulus inferior scapulae subcutaneous fat thickness before and after the test-meal.
Table 7
Grouping |
Right angulus inferior scapulae subcutaneous fat thickness (mm) before the test-meal |
Right angulus inferior scapulae subcutaneous fat thickness (mm) after the test-meal |
Difference |
The test-meal group |
24.25±7.50 |
20.97±5.52
*※ |
-3.28±2.89 |
Control group |
25.14±6.99 |
25.85±9.21 |
0.71±3.83 |
Compare between test front and back self and group: * own control P<0.05 contrasts P<0.01 between the ※ group.
Right angulus inferior scapulae subcutaneous fat thickness difference has conspicuousness (P<0.05), decreased average 3.28 ± 2.89mm before and after the test of test-meal group as can be seen from Table 7; Test back test-meal group and control group comparing difference have conspicuousness (P<0.01), illustrate that given the test agent has the effect that reduces right angulus inferior scapulae subcutaneous fat.
Table 8 changes (X ± SD) show for the other 3cm of right navel place subcutaneous fat thickness before and after the test-meal.
Table 8
Grouping |
The other 3cm place's subcutaneous fat thickness (mm) of navel before the test-meal |
The other 3cm place's subcutaneous fat thickness (mm) of test-meal posterior umbilicus |
Difference |
The test-meal group |
32.34±8.50 |
27.43±8.38
*※ |
-4.91±1.46 |
Control group |
32.20±8.04 |
32.04±10.68 |
-0.17±1.21 |
Compare between test front and back self and group: * own control P<0.01 contrasts P<0.05 between the ※ group.
The other 3cm of right navel place subcutaneous fat thickness difference has conspicuousness (P<0.01), decreased average 4.91 ± 1.46mm before and after the test of test-meal group as can be seen from Table 8; Test back test-meal group and control group comparing difference have conspicuousness (P<0.05), illustrate that given the test agent has the effect that reduces the other subcutaneous fat of right navel.
Table 9 changes (X ± SD) show for right anterior superior spine subcutaneous fat thickness before and after the test-meal.
Table 9
Grouping |
Right anterior superior spine subcutaneous fat thickness (mm) before the test-meal |
Right anterior superior spine subcutaneous fat thickness (mm) after the test-meal |
Difference |
The test-meal group |
29.67±5.66 |
25.25±7.74
*※ |
-4.41±2.95 |
Control group |
29.26±7.15 |
28.28±5.06 |
-0.98±1.62 |
Compare between test front and back self and group: * own control P<0.01 contrasts P<0.05 between the ※ group.
Right anterior superior spine subcutaneous fat thickness difference has conspicuousness (P<0.01), decreased average 4.41 ± 2.95mm before and after the test of test-meal group as can be seen from Table 9; Test back test-meal group and control group comparing difference have conspicuousness (P<0.05), illustrate that given the test agent has the effect that reduces right anterior superior spine subcutaneous fat.
Table 10 is the doing well,improving information slip of hidrosis before and after the test-meal, constipation and lassitude and weak.
Table 10
The efficient of the hidrosis of test-meal group as can be seen from Table 10, constipation and lassitude and weak is respectively 21.43%, 60.00% and 80.95%, the efficient of control group is respectively 11.54%, 16.67% and 27.27%, the test-meal group is compared with control group, and symptom obviously improves.
Table 11 changes (X ± SD) show for maximal oxygen uptake before and after the test-meal.
Table 11
Compare between maximal oxygen uptake self and group before and after the test-meal: P>0.05.
Maximal oxygen uptake before and after two groups of experimenters test as can be seen from Table 11, no matter self relatively still compares difference that there are no significant (P>0.05) between group.Before and after test-meal is described the ability to take oxygen in the human body is not had to change substantially.
Table 12 compares (X ± SD) show for meals heat before and after the test-meal.
Table 12
Compare between meals heat self and group before and after the test-meal: P>0.05.
Two groups of experimenters test front and back meals heat absorption as can be seen from Table 12, and no matter self relatively still compares difference that there are no significant (P>0.05) between group.Illustrate that test-meal people from front and back obviously do not change the intake of food.
Table 13 changes relatively (X ± SD) show for blood, urine and stool routine examination safety indexes before and after the test-meal.
Table 13
The above-mentioned every index in test front and back is all in normal range (NR) as can be seen from Table 13.
Table 14 is that test-meal front and back heart rate and blood pressure compare (X ± SD) show.
Table 14
Test-meal front and back heart rate and blood pressure index are all in normal range (NR) as can be seen from Table 14.
Spirit, sleep, diet, stool and urine etc. there is no unusual before and after experimenter's test-meal.
The hyperlipemia crowd of complication such as no severe cardiac, liver, kidney that will be 18~65 years old the age is as the experimenter; , organize in contrast as the test-meal group with the crowd of the edible resulting Weight-lossing hypolipemic medicine of the present invention, two groups of experimenters are kept carrying out under equal diet and the moving condition lipid-lowering effect test with the crowd of edible placebo.
Table 15 is the basic document of two groups of tests.
Table 15
Project |
Control group |
The test-meal group |
The example number |
52 |
51 |
Man/woman |
26/26 |
24/27 |
Age (year) |
45.56±4.65 |
43.46±8.10 |
Cholesterol (mmol/L) |
6.42±1.21 |
6.54±1.08 |
Triglycerides (mmol/L) |
2.34±0.86 |
2.47±0.97 |
Test all no significant differences (P>0.05) such as preceding two groups of patient ages, blood lipid level, have comparativity.
Table 16 detects index (X ± SD) show for hematology before and after the test-meal.
Table 16
The experimenter passes through routine blood test, blood biochemistry index, stool and urine routine inspection result all in normal range (NR) before and after the test as can be seen from Table 16.
Table 17 is that test-meal front and back heart rate and blood pressure compare (X ± SD) show.
Table 17
The experimenter passes through heart rate, blood pressure check result all in normal range (NR) before and after the test as can be seen from Table 17.
Table 18 changes (X ± SD) show for cholesterol before and after the test-meal.
Table 18
Group |
Example number (n) |
Cholesterol (mmol/L) before the test |
Test back cholesterol (mmol/L) |
Decline percentage (%) |
Efficient (%) |
Control group |
52 |
6.37±0.47 |
6.33±0.51 |
0.56±4.31 |
7.69 |
The test-meal group |
51 |
6.34±0.45 |
5.67±0.47
*※ |
10.48±5.11 |
56.86 |
* with before the test compare P=0.000, P<0.01; ※ and control group compare, P=0.000, P<0.01.
Cholesterol difference has conspicuousness (P<0.01) before and after the test of test-meal group as can be seen from Table 18; Test back test-meal group cholesterol and control group comparing difference have conspicuousness (P<0.01), and its percentage that on average descends is 13.11 ± 8.64%, and efficient is 56.86%, illustrate that given the test agent has the effect that reduces cholesterol.
Table 19 is the variation (X ± SD) show of triglycerides before and after the test-meal.
Table 19
Group |
Example number (n) |
Triglycerides (mmol/L) before the test |
Test back triglycerides (mmol/L) |
Decline percentage (%) |
Efficient (%) |
Control group |
52 |
2.35±0.71 |
2.27±0.68 |
2.83±12.77 |
26.92 |
The test-meal group |
51 |
2.41±0.59 |
1.93±0.52
**※ |
19.57±8.12 |
66.67 |
* with before the test compare P=0.000, P<0.01; ※ and control group compare, P=0.005, P<0.01.
Triglycerides difference has conspicuousness (P<0.01) before and after the test of test-meal group as can be seen from Table 19; Test back test-meal group triglycerides and control group comparing difference have conspicuousness (P<0.01), and its percentage that on average descends is 25.93 ± 24.82%, and efficient is 66.67%, illustrate that given the test agent has the effect that reduces triglycerides.
Table 20 is a clinical observation effect comparison sheet.
Table 20
Group |
Example number (n) |
Effectively |
Invalid |
Total effective rate % |
Control group |
52 |
6 |
46 |
11.54 |
The test-meal group |
51 |
27 |
24 |
52.94
※ |
※ and control group be χ relatively
2=20.270, P<0.01.
At the test-meal given the test agent after 45 days, test-meal group clinical observation total effective rate and control group comparing difference have conspicuousness (P<0.01), illustrate that given the test agent has obvious effects to the reducing blood lipid symptom as seen from Table 20.